Moreover, the apparent tumour specificity of the iRGD-induced reverse transport in tumours may provide a promising approach to overcome the difficulty of determining whether an increase of a potential circulating marker originates from a malignant tumour or from a non-malignant lesion that produces the marker, such as AFP in liver cancer vs. hepatitis. The gene discussed is AFP; the disease is Hepatitis.